Breakthrough Malaria Defenses: Vaccines, Drugs, and Transmission Blocking Strategies Advance Globally
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Breakthrough Malaria Defenses: Vaccines, Drugs, and Transmission Blocking Strategies Advance Globally
-
ナレーター：
-
著者：
このコンテンツについて
On the science front, two separate announcements converged on how to stop the parasite at different stages of its life cycle. Medical Xpress reports that new immunology data explain why the WHO‑recommended R21/Matrix‑M vaccine protects so effectively at the earliest stage of infection: antibodies elicited by R21 closely mimic those produced after natural infection, targeting the sporozoite form transmitted by mosquito bites. The study, published in the Journal of Experimental Medicine and led by Texas Biomedical Research Institute in collaboration with the University of Oxford’s Jenner Institute, helps clarify how R21 blocks the parasite before it reaches the bloodstream, the point at which symptoms begin, and underscores the role of the Matrix‑M adjuvant in boosting that response, according to Medical Xpress.
A complementary strategy—blocking transmission inside the mosquito—is advancing as well. Drug Target Review reports that Australian scientists at the Walter and Eliza Hall Institute have, for the first time, visualized a key malaria parasite fertilization complex using cryo‑electron microscopy, enabling the design of an mRNA vaccine candidate that induces antibodies to stop parasite reproduction in mosquitoes. According to Drug Target Review, this next‑generation approach aims to cut transmission by preventing the parasite from fertilizing and spreading within the vector, potentially breaking the human–mosquito cycle.
In Southeast Asia, Indonesia is preparing to test whether one vaccination regimen can protect against the two most widespread human malaria species. OUCRU (the Oxford University Clinical Research Unit) announced plans for a Phase 2 clinical trial in Keerom, Papua, that will co‑administer Oxford’s R21 for Plasmodium falciparum and the related Rv21 candidate for Plasmodium vivax. OUCRU notes this will be the first human trial of a dual‑species malaria vaccination strategy and, if successful, could be game‑changing for the Asia‑Pacific, where the burden of P. vivax remains high. The long‑term aim, OUCRU adds, is a single vaccination that protects against both species.
On the implementation side, vaccine rollout continues to expand in high‑burden settings. ReliefWeb reports that South Sudan has launched the second phase of its R21 malaria vaccine introduction across 52 counties to protect children. From July 2024 to May 2025, 148,878 children received a first dose, and authorities are working to accelerate coverage as the program scales, according to ReliefWeb. The update reflects growing momentum behind the WHO‑recommended vaccines for pediatric prevention in Africa.
Meanwhile, drug development efforts may soon bolster first‑line therapies threatened by resistance. News‑Medical reports that chemists at the University of California, San Francisco have re‑engineered a next‑generation antimalarial scaffold to improve solubility and oral dosing without sacrificing potency. The optimized compound matched the activity of the prior candidate artefenomel and outperformed artemisinin against artemisinin‑resistant parasites in preclinical tests, according to News‑Medical. The work, published in Science Advances, points to potential successors to current treatments that could be affordable and amenable to combination regimens.
Together, these updates sketch a multipronged strategy: R21 continues to show why it works in children by mimicking natural immunity against sporozoites, WEHI’s structural biology is powering transmission‑blocking mRNA vaccine candidates targeted inside mosquitoes, OUCRU is moving toward dual‑species protection in Indonesia, South Sudan is broadening pediatric rollout, and UCSF’s chemistry advances could strengthen the therapeutic backbone as resistance evolves.
まだレビューはありません